Searched for
SOVEREIGN PHARMA
India has wide AI talent gaps in deployment, governance, security: Quess reportIndia faces significant AI talent gaps in deployment, governance, and security roles, with GenAI deployment showing the widest deficit. Whi...- Japanese investors are looking beyond China... India is key alternative: Tsutomu Takemura, Senior MD, NomuraIndia is increasingly becoming a long-term structural investment destination rather than a short-term strategic bet. Global capital is movi...
- IAIRO appoints AvenuesAI's CMD Vishal Mehta as Technical AdvisorThe Indian AI Research Organisation (IAIRO), a fast-rising institution at the centre of India's sovereign artificial intelligence ambitions...
- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsFor the next few weeks, what needs to be watched is market breadth. And also look at which sectors are leading the rally. Why? Because, at ...
- Laurence Balanco flags 5% downside risk for Nifty amid global yield surgeGlobal financial markets are experiencing a risk-off shift driven by rising sovereign bond yields, impacting equities and commodities. Mark...
- As US reboots psychedelics from counterculture to R&D, Indian pharma must take the leadThe United States is accelerating research into psychedelic drugs for mental illness. This shift prompts India to re-evaluate its own drug ...
- SUSE eyes deeper India push as CEO flags growth, open-source demandSUSE plans to increase investments in India, recognizing it as a significant growth market for open-source technologies. The company aims t...
- ETMarkets Smart Talk: Indian bonds to gain global standing after rating upgrade, says Kashyap JaveriEmkay Investment Managers' Kashyap Javeri believes India's sovereign rating upgrade and inclusion in global bond indices will attract signi...
- Mubadala plans big deals in India's healthcare spaceAbu Dhabi's Mubadala Investment Company plans to expand in India's healthcare sector, seeking deals in the $200-500 million range. With a f...
- 3 pharma stocks to buy on dips; 3 banks that may outperform: Sanjiv Bhasin“ HDFC Bank is a very good long-term and a slightly medium-term play. I do not rule out Bank Nifty going back to test 46,000 in this month ...
- Abu Dhabi Sovereign Fund to buy into Intas PharmaADIA, with assets under management worth $800 billion, has a wide exposure in India. Its major investments include Flipkart, Reliance Retai...
- Gland Pharma expects to begin exports of single shot Sputnik Light vaccine by NovemberAs per RDIF, Sputnik Light has been authorized in more than 15 countries. Gland Pharma said it is focusing on rolling out the single shot S...
- Gland Pharma buys Vitane’s assets to scale up production of Sputnik VVitane Biologics, with around 100 personnel, has a dedicated research and development facility and a manufacturing plant to handle both mic...
- Use sovereign rights to grant compulsory license for vaccine, medicines: SJM to govt“We understand that the government needs to use the public health safeguards in the Patents Act and permit more companies to produce these ...
- PM Narendra Modi to meet officials of top global SWFs, PFsModi will chair the Virtual Global Investor Roundtable (VGIR) that will also see participation from domestic industry.
- 80% jump in 6 months, Covid vaccine can give this stock a shot in the armOpportunity to launch a vaccine would mean one-time exceptional business gain, brand boost
- Cipla launches generic version of remdesivir at Rs 4,000 per vial"We are proud to commercially launch Cipremi today (on Wednesday); amongst the lowest priced globally, and aim to supply over 80,000 vials ...
- Hetero, Cipla to supply generic Remdesivir to hospitals this weekThe recommended course for a Covid-19 patient under oxygen support is five vials. The approved therapy is for moderate to severe patients.
- Indoco in talks to sell part of India operationsIndoco’s domestic formulations sales for the year ended March 31, 2018, were flat at Rs 595 crore, as against Rs 585 crore last year (growt...
- After a profit warning, Sun Pharma seeks to tap global debt market to raise $1 billion“The size of the bond issuance is expected to be in the range of $500-1,000 million with five- to 10-year maturities, depending on its pric...
Load More
